Partnering
Cantab Biopharmaceuticals Ltd is advancing its product pipeline of biosuperiors to points of significant value.
In parallel to this, CBL is evaluating new biological medicine targets within multiple therapeutic areas. CBL is evaluating opportunities to in-licence or acquire technology applicable to biosuperior drug development.
Please feel free to contact us for more information about possible strategic collaborations if you have either novel, IP protected technology to out-licence or wish to acquire the next generation of biological medicines.